68 related articles for article (PubMed ID: 16618115)
1. Interaction of the indole class of vacuolar H(+)-ATPase inhibitors with lipid bilayers.
Fernandes F; Loura L; Koehorst RB; Dixon N; Kee TP; Hemminga MA; Prieto M
Biochemistry; 2006 Apr; 45(16):5271-9. PubMed ID: 16618115
[TBL] [Abstract][Full Text] [Related]
2. (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6- pentamethylpiperidin-4-yl)-2,4-pentadienamide, a novel, potent and selective inhibitor of the osteoclast V-ATPase.
Nadler G; Morvan M; Delimoge I; Belfiore P; Zocchetti A; James I; Zembryki D; Lee-Rycakzewski E; Parini C; Consolandi E; Gagliardi S; Farina C
Bioorg Med Chem Lett; 1998 Dec; 8(24):3621-6. PubMed ID: 9934482
[TBL] [Abstract][Full Text] [Related]
3. Membrane-bound peptides from V-ATPase subunit a do not interact with an indole-type inhibitor.
Hesselink RW; Fedorov A; Hemminga MA; Prieto M
J Pept Sci; 2008 Apr; 14(4):383-8. PubMed ID: 18069732
[TBL] [Abstract][Full Text] [Related]
4. Concanamycin and indolyl pentadieneamide inhibitors of the vacuolar H+-ATPase bind with high affinity to the purified proteolipid subunit of the membrane domain.
Whyteside G; Meek PJ; Ball SK; Dixon N; Finbow ME; Kee TP; Findlay JB; Harrison MA
Biochemistry; 2005 Nov; 44(45):15024-31. PubMed ID: 16274249
[TBL] [Abstract][Full Text] [Related]
5. Interaction of inhibitors of the vacuolar H(+)-ATPase with the transmembrane Vo-sector.
Páli T; Whyteside G; Dixon N; Kee TP; Ball S; Harrison MA; Findlay JB; Finbow ME; Marsh D
Biochemistry; 2004 Sep; 43(38):12297-305. PubMed ID: 15379568
[TBL] [Abstract][Full Text] [Related]
6. New biophysical probes for structure-activity analyses of vacuolar-H+ -ATPase enzymes.
Dixon N; Pali T; Ball S; Harrison MA; Marsh D; Findlay JB; Kee TP
Org Biomol Chem; 2003 Dec; 1(24):4361-3. PubMed ID: 14685305
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of the V-ATPase inhibitors concanamycin and indole pentadiene in lipid membranes. Spin-label EPR studies.
Páli T; Dixon N; Kee TP; Marsh D
Biochim Biophys Acta; 2004 May; 1663(1-2):14-8. PubMed ID: 15157605
[TBL] [Abstract][Full Text] [Related]
8. A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats.
Visentin L; Dodds RA; Valente M; Misiano P; Bradbeer JN; Oneta S; Liang X; Gowen M; Farina C
J Clin Invest; 2000 Jul; 106(2):309-18. PubMed ID: 10903347
[TBL] [Abstract][Full Text] [Related]
9. Antimetastatic effect of a small-molecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies.
Supino R; Petrangolini G; Pratesi G; Tortoreto M; Favini E; Bo LD; Casalini P; Radaelli E; Croce AC; Bottiroli G; Misiano P; Farina C; Zunino F
J Pharmacol Exp Ther; 2008 Jan; 324(1):15-22. PubMed ID: 17909082
[TBL] [Abstract][Full Text] [Related]
10. Interaction of spin-labeled inhibitors of the vacuolar H+-ATPase with the transmembrane Vo-sector.
Dixon N; Páli T; Kee TP; Ball S; Harrison MA; Findlay JB; Nyman J; Väänänen K; Finbow ME; Marsh D
Biophys J; 2008 Jan; 94(2):506-14. PubMed ID: 17872954
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of osteoclast vacuolar H(+)-ATPase.
Farina C; Gagliardi S
Curr Pharm Des; 2002; 8(23):2033-48. PubMed ID: 12171517
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of photoactivable inhibitors of osteoclast vacuolar ATPase.
Biasotti B; Dallavalle S; Merlini L; Farina C; Gagliardi S; Parini C; Belfiore P
Bioorg Med Chem; 2003 May; 11(10):2247-54. PubMed ID: 12713834
[TBL] [Abstract][Full Text] [Related]
13. Vacuolar ATPase as a drug discovery target.
Niikura K
Drug News Perspect; 2006 Apr; 19(3):139-44. PubMed ID: 16804565
[TBL] [Abstract][Full Text] [Related]
14. FR177995, a novel vacuolar ATPase inhibitor, exerts not only an inhibitory effect on bone destruction but also anti-immunoinflammatory effects in adjuvant-induced arthritic rats.
Niikura K; Nakajima S; Takano M; Yamazaki H
Bone; 2007 Apr; 40(4):888-94. PubMed ID: 17157574
[TBL] [Abstract][Full Text] [Related]
15. The little we know on the structure and machinery of V-ATPase.
Saroussi S; Nelson N
J Exp Biol; 2009 Jun; 212(Pt 11):1604-10. PubMed ID: 19448070
[TBL] [Abstract][Full Text] [Related]
16. SB 242784, a selective inhibitor of the osteoclastic V-H+ATPase, inhibits arterial calcification in the rat.
Price PA; June HH; Buckley JR; Williamson MK
Circ Res; 2002 Sep; 91(6):547-52. PubMed ID: 12242274
[TBL] [Abstract][Full Text] [Related]
17. A new destruxin as inhibitor of vacuolar-type H+-ATPase of Saccharomyces cerevisiae.
Vázquez MJ; Albarrán MI; Espada A; Rivera-Sagredo A; Díez E; Hueso-Rodríguez JA
Chem Biodivers; 2005 Jan; 2(1):123-30. PubMed ID: 17191925
[TBL] [Abstract][Full Text] [Related]
18. Electrostatic contributions to indole-lipid interactions.
Gaede HC; Yau WM; Gawrisch K
J Phys Chem B; 2005 Jul; 109(26):13014-23. PubMed ID: 16852615
[TBL] [Abstract][Full Text] [Related]
19. The vacuolar-ATPase inhibitor bafilomycin and mutant VPS35 inhibit canonical Wnt signaling.
George A; Leahy H; Zhou J; Morin PJ
Neurobiol Dis; 2007 Apr; 26(1):125-33. PubMed ID: 17239604
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel analogues of archazolid: a highly potent simplified V-ATPase inhibitor.
Menche D; Hassfeld J; Sasse F; Huss M; Wieczorek H
Bioorg Med Chem Lett; 2007 Mar; 17(6):1732-5. PubMed ID: 17239591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
